Brokerages Set Sarepta Therapeutics, Inc. (NASDAQ:SRPT) PT at $183.89

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has been assigned an average recommendation of “Moderate Buy” from the twenty-one ratings firms that are currently covering the stock, MarketBeat Ratings reports. Two analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1-year price target among brokers that have covered the stock in the last year is $182.95.

A number of research firms have recently weighed in on SRPT. Evercore ISI raised shares of Sarepta Therapeutics from an “in-line” rating to an “outperform” rating and dropped their price target for the stock from $185.00 to $179.00 in a research note on Thursday, August 8th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $182.00 price target on shares of Sarepta Therapeutics in a research note on Monday. Needham & Company LLC reaffirmed a “buy” rating and issued a $205.00 price target on shares of Sarepta Therapeutics in a research note on Monday, October 14th. Raymond James reaffirmed an “outperform” rating and issued a $150.00 price target on shares of Sarepta Therapeutics in a research note on Thursday, October 10th. Finally, Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $152.00 price target on shares of Sarepta Therapeutics in a research note on Friday, September 20th.

Sarepta Therapeutics Price Performance

SRPT opened at $132.02 on Friday. The stock has a fifty day moving average of $128.78 and a 200-day moving average of $132.40. The firm has a market capitalization of $12.48 billion, a P/E ratio of 1,200.18 and a beta of 0.82. Sarepta Therapeutics has a 12-month low of $55.25 and a 12-month high of $173.25. The company has a quick ratio of 3.19, a current ratio of 3.90 and a debt-to-equity ratio of 1.05.

Sarepta Therapeutics (NASDAQ:SRPT) last released its earnings results on Wednesday, August 7th. The biotechnology company reported $0.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.01 by $0.06. Sarepta Therapeutics had a return on equity of 5.32% and a net margin of 3.14%. The company had revenue of $362.90 million during the quarter, compared to analyst estimates of $394.38 million. During the same quarter in the prior year, the company earned ($0.27) earnings per share. The company’s revenue for the quarter was up 38.9% on a year-over-year basis. Equities analysts forecast that Sarepta Therapeutics will post 1.45 EPS for the current fiscal year.

Insider Activity

In other news, CFO Ian Michael Estepan sold 5,985 shares of the firm’s stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $137.36, for a total value of $822,099.60. Following the sale, the chief financial officer now directly owns 33,946 shares of the company’s stock, valued at approximately $4,662,822.56. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In related news, Director Michael Andrew Chambers bought 37,038 shares of Sarepta Therapeutics stock in a transaction that occurred on Friday, August 16th. The stock was acquired at an average price of $133.80 per share, for a total transaction of $4,955,684.40. Following the completion of the purchase, the director now owns 284,034 shares in the company, valued at approximately $38,003,749.20. This represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Ian Michael Estepan sold 5,985 shares of the stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $137.36, for a total transaction of $822,099.60. Following the completion of the sale, the chief financial officer now owns 33,946 shares of the company’s stock, valued at approximately $4,662,822.56. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. 7.70% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Sarepta Therapeutics

Hedge funds have recently made changes to their positions in the stock. Nordea Investment Management AB lifted its stake in shares of Sarepta Therapeutics by 120.6% in the first quarter. Nordea Investment Management AB now owns 61,657 shares of the biotechnology company’s stock valued at $8,004,000 after buying an additional 33,711 shares during the period. Fifth Third Wealth Advisors LLC bought a new position in Sarepta Therapeutics during the second quarter worth about $607,000. Teachers Retirement System of The State of Kentucky bought a new position in Sarepta Therapeutics during the second quarter worth about $4,771,000. Securian Asset Management Inc. bought a new position in Sarepta Therapeutics during the second quarter worth about $1,187,000. Finally, Natixis Advisors LLC bought a new position in Sarepta Therapeutics during the second quarter worth about $1,918,000. Institutional investors own 86.68% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.